Low-dose IL-2 treatment in the mid-stages of AD restores the Treg/Th17 balance, reduces neuroinflammation, and decreases amyloid plaque burden in APP/PS1 (Amyloid Precursor Protein/Presenilin-1) models, significantly improving cognition (78). This evidence concerns the gene PSEN1 and amyloidosis.